Table 1.
Patient characteristics
| Characteristic | Number of patients (N = 124) | |
|---|---|---|
| Median age, years (range) | 63 (23–79) | |
| Gender | Male/female | 74/50 |
| Performance status | 0–1/2 | 111/13 |
| Pathology | Wel or mod/por | 113/11 |
| Peritoneal metastasis | Yes/no | 26/98 |
| Liver metastasis | Yes/no | 69/55 |
| Metastatic sites | 1–2/> 3 | 99/25 |
| First-line treatment | FOLFOX/FOLFOX+BV | 107/17 |
| Response to first-line FOLFOX | CR/PR/SD/PD | 0/54/47/23 |
| PFS of first-line FOLFOX | < 6 months/> 6 months | 49/75 |
| Cause of oxaliplatin discontinuation | Disease progression/other | 65/59 |
| Leukocyte count (/L) | < 8×109/≥ 8×109 | 110/14 |
| ALP (IU/L) | < 400/≥ 400 | 70/54 |
| LDH (IU/L) | < 400/≥ 400 | 98/26 |
| CEA (ng/mL) | < 500/> 500 | 110/14 |
Abbreviations: ALP = alkaline phosphatase; CEA = carcinoembryonic antigen; CR = complete response; LDH = lactate dehydrogenase; mod = moderately differentiated adenocarcinoma; PD = progressive disease; PFS = progression-free survival; por = poorly differentiated adenocarcinoma; PR = partial response; SD = stable disease; wel = well-differentiated adenocarcinoma.